An interim safety analysis of hepatocellular carcinoma patients administrating oral vitamin K with or without sorafenib
Korean Journal of Hepato-Biliary-Pancreatic Surgery
;
: 1-5, 2015.
Artículo
en Inglés
| WPRIM
| ID: wpr-47880
ABSTRACT
BACKGROUNDS/AIMS:
Vitamin K may plays a role in controlling hepatocellular carcinoma (HCC) cell growth. In this study, we intended to present 5-year experience of 72 patients receiving oral vitamin K with or without sorafenib. Its end-point was to evaluate the safety of combination therapy using sorafenib and vitamin K.METHODS:
An interim analysis was performed as a single-arm cross-sectional study, including 72 HCC patients who underwent liver resection or transplantation and administered oral vitamin K2 alone (n=47) or with sorafenib (n=25).RESULTS:
In all patients, administration of vitamin K2 analog 45 mg/day did not show any noticeable adverse side-effect during vitamin K therapy of 23.3+/-10.6 months, except for one patient who experienced skin rash at the third day of vitamin K therapy. In 25 patients receiving sorafenib and vitamin K for 6 months or longer, any noticeable adverse side-effect suspected of vitamin K origin was not identified yet. A small proportion of patients showed unexpectedly favorable anti-tumor effects after use of vitamin K with or without sorafenib.CONCLUSIONS:
Because add-on of oral vitamin K did not increase the adverse side-effects of sorafenib, a combination therapy with these two agents appears to be worthy of further clinical trial with an expectation of synergistic therapeutic effects.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Vitamina K
/
Estudios Transversales
/
Carcinoma Hepatocelular
/
Vitamina K 2
/
Exantema
/
Hígado
/
Metástasis de la Neoplasia
Tipo de estudio:
Ensayo Clínico Controlado
/
Estudio observacional
/
Estudio de prevalencia
/
Factores de riesgo
Límite:
Humanos
Idioma:
Inglés
Revista:
Korean Journal of Hepato-Biliary-Pancreatic Surgery
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS